Kestra Medical Technologies reported first-quarter results that showed rapid revenue growth alongside a widening net loss, while the company lifted full-year 2027 revenue guidance. Shares rose in the regular session after the earnings release, but the stock was lower in early trading afterward, reflecting investors’ focus on profitability as well as growth.
For the quarter ended July 31, 2026, net loss widened to $44.09 million, or $0.75 per share, from $25.83 million, or $0.50 per share, a year earlier. Revenue increased 60% to $30.97 million from $19.37 million, supported by expansion in the wearable cardioverter defibrillator market, competitive share gains and new sales territories, the company said.
Key takeaways
- Stock move: Kestra Medical shares closed Monday up 5.30% at $24.06, though they fell 11.72% to $21.24 in the overnight market.
- Catalyst: Revenue growth of 60% in the latest quarter, coupled with an increase in full-year 2027 revenue guidance.
- Profitability pressure: Net loss expanded to $44.09 million as operating loss rose to $37.66 million from $28.88 million.
- Forward-looking implication: The raised outlook suggests confidence in demand and commercial execution, but investors will likely keep watching cost structure and losses.
What drove the quarterly results
Kestra Medical’s business is centered on cardiovascular disease management through connected monitoring and therapeutic intervention, with data-driven clinical insights. The company’s Cardiac Recovery System is positioned as an integrated platform aimed at patients considered at elevated risk of sudden cardiac arrest (SCA) during recovery periods.
In the reported quarter, the company attributed the 60% revenue jump to a combination of market expansion for wearable cardioverter defibrillators (WCDs), gains against competitors, and sales growth into new territories. Management linked the higher revenue base to improved commercial traction across its installed ecosystem and patient-monitoring workflow.
However, the bottom-line result showed the company is still investing heavily. Operating loss increased to $37.66 million from $28.88 million a year earlier, which fed through to the wider net loss. The results indicate that near-term growth is still outpacing cost containment.
Guidance raised for full-year 2027
Alongside its quarterly reporting, Kestra Medical increased its revenue outlook for full-year 2027 to $141 million from the prior projection of $137 million. The company described this as representing growth of 48% versus $95.1 million in 2026.
While the upward revision is relatively modest compared with the overall growth trajectory implied for 2027, it signals management’s confidence in sustaining commercial momentum. For investors, the key question is whether continued market penetration and share gains can eventually translate into improved leverage—reducing losses as revenue scales.
Liquidity position and trading context
As of July 31, 2026, Kestra Medical reported cash and cash equivalents and investments totaling $244.7 million. That balance provides a meaningful liquidity buffer as the company pursues operating scale, though the widening losses underline that investors will likely scrutinize future spending efficiency and the timing of any progress toward profitability.
The stock has traded in a 52-week range of $17.34 to $30.00. Monday’s close at $24.06 marked a positive reaction to the results and guidance, but the subsequent decline in the overnight session suggests some market participants may have been less convinced by the cost trajectory despite stronger top-line momentum.
What to watch next
Investors will likely focus on whether Kestra Medical’s revenue gains broaden further while operating loss narrows in subsequent quarters. In the near term, the company’s next earnings report and updates to guidance will be key, particularly for any signals on expense discipline and how quickly commercial expansion can translate into margin improvement.
